Design Therapeutics, Inc.

Design Therapeutics, Inc. (DSGN) priced its initial public offering on Mar 26, 2021 at $20.00 per share, within its $18.00–$20.00 range, raising $240M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.08B. Goldman Sachs was lead-left underwriter, joined by Leerink Partners and Piper Sandler. Cooley advised the company and Latham & Watkins advised the underwriters.

Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing small-molecule gene targeted chimeras, or GeneTACs, to treat inherited nucleotide repeat expansion diseases. Targets include Friedreich ataxia, myotonic dystrophy type 1, Fuchs endothelial corneal dystrophy and Huntington disease.

Status

IPO

Ticker

DSGN

Exchange

Nasdaq Global Select

Priced

Mar 26, 2021

IPO price

$20.00

Price range

$18.00–$20.00

Raised

$240M

Market cap at IPO price

$1.08B

First filed

Mar 5, 2021

Underwriters

Goldman Sachs, Leerink Partners and Piper Sandler

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.